Get the Stockscreener App
16.86
10.18%
-1.91
After Hours:
16.85
-0.010
-0.06%
Enliven Therapeutics Inc stock is traded at $16.86, with a volume of 1.41M.
It is down -10.18% in the last 24 hours and down -16.95% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$18.77
Open:
$18.7
24h Volume:
1.41M
Relative Volume:
2.36
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-8.9206
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-22.70%
1M Performance:
-16.95%
6M Performance:
-14.24%
1Y Performance:
-26.70%
1-Day Range:
$16.62
$18.81
1-Week Range:
$16.62
$22.07
52-Week Range:
$13.30
$25.37
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
16.86 | 1.11B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression - BioCentury
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock - MarketBeat
Enliven Therapeutics (Nasdaq: ELVN) approves 875K-share inducement option for CEO at $18.77 - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling - MarketBeat
Enliven Therapeutics appoints Rick Fair as new CEO - Investing.com
Enliven Therapeutics, Inc. Announces Management Changes - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO, shares down - TradingView — Track All Markets
Enliven Therapeutics Appoints Rick Fair as CEO - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO By Investing.com - Investing.com South Africa
Enliven Therapeutics Appoints New CEO and Director - TradingView — Track All Markets
Enliven Therapeutics announces new CEO to drive next phase of development - marketscreener.com
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PR Newswire
Top investors say Enliven Therapeutics Inc (ELVN) ticks everything they need - setenews.com
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Yahoo Finance
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Trading the Move, Not the Narrative: (ELVN) Edition - news.stocktradersdaily.com
Enliven Therapeutics: ENABLE trial shows promise in treating atypical fusion CML - Traders Union
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Enliven Therapeutics Inc stock benefit from AI adoptionJuly 2025 Setups & Long-Term Capital Growth Strategies - moha.gov.vn
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) and PreveCeutical Medical (OTCMKTS:PRVCF) Head-To-Head Analysis - Defense World
Can Enliven Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - Newser
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound - Sahm
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Ready to Jump After Recent Trade: Enliven Therapeutics Inc (ELVN) - setenews.com
Will Enliven Therapeutics Inc. stock keep outperforming rivals2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Enliven Therapeutics Inc. stock ready for breakout2025 Volume Leaders & Long-Term Growth Stock Strategies - Newser
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8%Time to Sell? - MarketBeat
Geode Capital Management LLC Grows Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Franklin Resources Inc. Has $8.63 Million Stock Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Risks Report: Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Macro Impact & Smart Swing Trading Alerts - BỘ NỘI VỤ
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Fundamental Recap & Weekly Breakout Watchlists - BỘ NỘI VỤ
Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? - MSN
(ELVN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Enliven Therapeutics Inc (ELVN) is looking forward to a strong quarter - setenews.com
SG Americas Securities LLC Buys 23,261 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics targets CML drug resistance breakthrough - Traders Union
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $279,125.00 in Stock - MarketBeat
Enliven Therapeutics Insider Sold Shares Worth $279,155, According to a Recent SEC Filing - MarketScreener
Officer Lyssikatos Sells 12,500 ($279.2K) Of Enliven Therapeutics Inc [ELVN] - TradingView
[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity - Stock Titan
Will Enliven Therapeutics Inc. stock outperform international peersWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
How Enliven Therapeutics Inc. stock reacts to Fed rate cutsGlobal Markets & Daily Technical Forecast Reports - newser.com
Why Enliven Therapeutics Inc. stock is favored by pension fundsWall Street Watch & Low Drawdown Investment Ideas - newser.com
What hedge fund activity signals for Enliven Therapeutics Inc. stock2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Is Enliven Therapeutics Inc. stock positioned well for digital economyMarket Risk Analysis & Expert-Curated Trade Recommendations - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
Enliven Therapeutics CEO Kintz sells $272k in shares By Investing.com - Investing.com Canada
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):